A compounding pharmacy under inspection is judged against two documents: the master formulation record and the compounding record. The master formulation record is the approved recipe for a preparation, written once and followed every time it is made again, while the compounding record documents that one specific batch actually followed it, down to the component lot numbers and the beyond-use date assigned that day. Inspectors from a state board of pharmacy, and in some matters the Food and Drug Administration (FDA), build citations out of a mismatch between the two records or a gap in either one.
The Master Formulation Record Sets the Recipe
USP <795>, the United States Pharmacopeia chapter governing nonsterile compounding, requires a pharmacy to create a master formulation record before compounding a preparation for the first time, and to follow it every time afterward. A 2026 self-inspection worksheet published by Washington's pharmacy board, which incorporates USP <795> into state pharmacy law, quotes the chapter's current content requirements: the preparation's name, strength, and dosage form, the identity and amount of every component, the equipment and steps needed to reproduce it, the assigned beyond-use date and its supporting reference, and the quality control procedures expected on the finished preparation. Sterile preparations made from nonsterile ingredients, or prepared for more than one patient, carry the same obligation under USP 797/800. Changing an ingredient source, a piece of equipment, or any compounding step is a reason to revise the master formulation record itself, not a note on a single batch's paperwork.
The Compounding Record Proves What Happened to One Batch
Where the master formulation record describes the recipe, the compounding record documents that one batch followed it. The same chapter requires the compounding record to carry the master formulation record reference it followed, the lot numbers and expiration dates of every component actually used, the total quantity compounded, the date of preparation, the beyond-use date assigned to that batch, and the names of the person who prepared it and the person who reviewed it. Review must happen before release, with the reviewer's name and the date of review on the record itself, not added later. USP <795> does not fix one national retention period for either record; how long to keep them is a question for the pharmacy's own state board of pharmacy rule.
What Comes From FDA and What Comes From USP
The master formulation record and the compounding record are USP requirements, not FDA ones. FDA's own summary of which Food, Drug, and Cosmetic Act provisions apply to 503A compounding exempts 503A pharmacies from federal current good manufacturing practice (cGMP), and FDA's separate guidance on insanitary conditions at compounding facilities does not name either record. That requirement reaches a 503A pharmacy through its state board of pharmacy; Washington's board, for example, has adopted USP <795> and <797> into state pharmacy law, and a pharmacy should check whether its own state board has done the same. A 503B outsourcing facility answers to a different federal rule instead, the batch production record requirement at 21 C.F.R. 211.188. Treating one regime as the other misstates what a 503A pharmacy has to produce on inspection.
A master formulation record that does not match its compounding record is the fastest route from a routine inspection to a documented finding.
The Documentation Gaps Inspectors Cite
A compounding record falls short of the chapter's requirements in three recognizable ways. The first is a missing lot number or expiration date for a component actually used, so the record cannot show what went into that batch. The second is a deviation from the master formulation record, a substituted ingredient or a different mixing step, never written down as a deviation when it happened. The third is a record completed after the preparation was already released, so the review the chapter requires before release could not actually have happened on time. A pharmacy's personnel training and competency records raise the same problem when the named reviewer cannot be shown to have been qualified to review it. Each gap turns documentation meant to prove compliance into evidence of the opposite.
Why Early Legal Counsel Is Critical
It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a state board inspection finding, an FDA Form 483, or any other government inquiry tied to master formulation record or compounding record gaps. Early legal intervention can protect the pharmacy's rights, shape the documentation response before an isolated gap is read as a pattern, avoid inadvertent admissions during the records exchange, and allow counsel to communicate with the inspecting agency on the pharmacy's behalf. Delaying representation can narrow the pharmacy's options once the inspector has already drawn conclusions from an incomplete record.
How Health Law Alliance Can Help
Health Law Alliance has represented 2,500+ clients nationwide. If your compounding pharmacy has received an inspection finding tied to a master formulation record, a compounding record, or any other documentation gap, contact Health Law Alliance's compounding pharmacy defense attorneys for a free, confidential consultation before the response deadline passes.
